NASDAQ:EMBC Embecta (EMBC) Stock Price, News & Analysis $12.37 -0.15 (-1.20%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$11.68 -0.68 (-5.54%) As of 08:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Embecta Stock (NASDAQ:EMBC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Embecta alerts:Sign Up Key Stats Today's Range$12.17▼$12.6050-Day Range$12.28▼$19.4052-Week Range$9.93▼$21.48Volume639,707 shsAverage Volume440,585 shsMarket Capitalization$719.12 millionP/E Ratio12.37Dividend Yield4.85%Price Target$23.00Consensus RatingModerate Buy Company OverviewEmbecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Read More… Remove Ads Embecta Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks96th Percentile Overall ScoreEMBC MarketRank™: Embecta scored higher than 96% of companies evaluated by MarketBeat, and ranked 30th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingEmbecta has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageEmbecta has received no research coverage in the past 90 days.Read more about Embecta's stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth7.72% Earnings GrowthEarnings for Embecta are expected to grow by 7.72% in the coming year, from $2.85 to $3.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Embecta is 12.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.57.Price to Earnings Ratio vs. SectorThe P/E ratio of Embecta is 12.37, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.21.Price to Earnings Growth RatioEmbecta has a PEG Ratio of 0.78. PEG Ratios below 1 indicate that a company could be undervalued.Read more about Embecta's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.46% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Embecta has recently decreased by 17.04%, indicating that investor sentiment is improving significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend LeadershipEmbecta is a leading dividend payer. It pays a dividend yield of 4.83%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthEmbecta does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Embecta is 60.00%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Embecta will have a dividend payout ratio of 19.54% next year. This indicates that Embecta will be able to sustain or increase its dividend.Read more about Embecta's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.46% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Embecta has recently decreased by 17.04%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment1.02 News SentimentEmbecta has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Embecta this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for EMBC on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows2 people have added Embecta to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Embecta insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $50,778.00 in company stock.Percentage Held by InsidersOnly 0.42% of the stock of Embecta is held by insiders.Percentage Held by Institutions93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Embecta's insider trading history. Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Email Address EMBC Stock News HeadlinesEmbecta announces new publication in Mayo Clinic Proceedings on FITTERApril 2 at 12:03 PM | markets.businessinsider.comEmbecta Flat on Publication of Diabetes Education PieceApril 1 at 2:03 PM | baystreet.caTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionApril 4, 2025 | Crypto 101 Media (Ad)Mayo Clinic Proceedings Publishes New Global Insulin Injection RecommendationsApril 1 at 8:05 AM | globenewswire.comEmbecta Insider Ups Holding By 20% During YearMarch 1, 2025 | finance.yahoo.comEmbecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In FavourFebruary 28, 2025 | seekingalpha.comEmbecta Corp. (EMBC): Among Last Week’s Worst Dividend StocksFebruary 19, 2025 | msn.comembecta to Participate at the J.P. Morgan Global Leveraged Finance ConferenceFebruary 18, 2025 | globenewswire.comSee More Headlines EMBC Stock Analysis - Frequently Asked Questions How have EMBC shares performed this year? Embecta's stock was trading at $20.65 on January 1st, 2025. Since then, EMBC stock has decreased by 40.1% and is now trading at $12.37. View the best growth stocks for 2025 here. How were Embecta's earnings last quarter? Embecta Corp. (NASDAQ:EMBC) announced its quarterly earnings data on Thursday, February, 6th. The company reported $0.65 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative trailing twelve-month return on equity of 19.22%. How do I buy shares of Embecta? Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Embecta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Embecta investors own include Waste Connections (WCN), AUO (AUOTY), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings2/06/2025Record date for 3/14 Dividend2/28/2025Ex-Dividend for 3/14 Dividend2/28/2025Dividend Payable3/14/2025Today4/03/2025Next Earnings (Estimated)5/08/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:EMBC CIK1872789 Webwww.embecta.com Phone201-847-6880FaxN/AEmployees1,900Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$26.00 Low Stock Price Target$20.00 Potential Upside/Downside+85.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$1.00 Trailing P/E Ratio12.37 Forward P/E Ratio4.34 P/E Growth0.78Net Income$78.30 million Net Margins5.25% Pretax Margin2.64% Return on Equity-19.22% Return on Assets11.92% Debt Debt-to-Equity RatioN/A Current Ratio2.24 Quick Ratio1.67 Sales & Book Value Annual Sales$1.11 billion Price / Sales0.65 Cash Flow$2.86 per share Price / Cash Flow4.32 Book Value($13.23) per share Price / Book-0.93Miscellaneous Outstanding Shares58,134,000Free Float57,890,000Market Cap$719.12 million OptionableOptionable Beta1.27 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:EMBC) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.